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standing. Internal validity was tested, assessing internal consistency, correlation
matrix using item/dimension correlation, factorial structure and differential item
functioning. External validation was performed versus motor symptoms, behav-
ioral symptoms, and the well-established QoL scale EuroQoL 5D. RESULTS: The
preliminary analysis supported the validity of the H-QoL-I. Face validity appeared
satisfactory (Missing data 7%); as for the original instrument, a ceiling effect was
observed for patients with severe HD. The H-QoL-I showed an acceptable reliability
(Cronbach’s alpha 0.85 for each dimension). The factor analysis explained 77% of
the total variance and split the items in 3 factors in the same way as the original
version. There was no differential item functioning neither between countries nor
gender. The Pearson’s correlation between the clinical motor score and the motor
functioning dimension was 0.89, between EQ-5D score and H-QoL-I total score, 0.71
and between the clinical depression/anxiety score and the psychological dimen-
sion of H-QoL-I, 0.63. CONCLUSIONS: Test–retest and sensitivity to change remain
to be performed, but current data support the validity of the H-QoL-I.
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OBJECTIVES: The H-CSRI is the first clinimetric patient assessed scale for patients
with Huntington’s disease (HD). It was originally developed and validated for
France and Italy. Such an instrument offers the advantage of allowing a remote
follow-up and getting information on the development of motor, functional and
behavioral disorders of HD patients perceived by the patient himself. The objective
of this study is to adapt and cross-culturally validate the H-CSRI for Germany,
Poland and USA. METHODS: The original questionnaire included three subscales
assessing the motor (13 Likert-type items in 4 dimensions), functional (7 Yes/No
questions) and behavioural ability (13 Likert-type items in 4 dimensions). The in-
strument was translated forwards and backwards by native speakers. It was then
reviewed and adjusted by local clinicians and tested for face validity. A total of 134
US, 60 Polish and 41 German HD patients filled in the H-CSRI questionnaire. Clas-
sical test theory and item response theory were used to assess its clinimetric prop-
erties.Cross-cultural validation was assessed by diferential item functioning
analysis. RESULTS: Among 235 patients, item response rates ranged from 86% to
93%. Face validity appeared satisfactory; as for the original instrument, there was a
floor effect on items related to psychotic disorder in the behavioral dimension. The
H-CSRI showed an acceptable reliability (Cronbach’s alphas 0.80). Factor analyses
demonstrated a satisfactory construct validity for the motor dimensions with 76%
of explained variance and for the behavioural dimensions with 74% of the ex-
plained variance. The differential item functioning analyses showed no item bias
between the three countries and between genders. CONCLUSIONS: These data
support the cross-cultural validity of the H-CSRI to assess the health status for
patients with Huntington’s disease and integrate the patient perspective for Ger-
many, Poland and US.
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OBJECTIVES: Ichthyoses form a group of ailments for which the main part of treat-
ment aims to reduce hyperkeratosis and to control sensory, articular and psycho-
logical complications. In infants, dermatologists do not restrict their treatment to
the cutaneous involvement, but endeavour to prevent the consequences of these
severe and obvious afflictions for the future of these patients. To explore the hand-
icap, in the largest sense, generated by ichthyosis using a questionnaire to express
the burden of the illness on the daily life of patients and their family, in order to
anticipate and treat it more effectively. METHODS: The questionnaire was devel-
oped following a strict methodological process involving a multidisciplinary team
incorporating various players (doctors, nurses, social workers) who are involved in
the treatment of patients and caring for their families in order to guarantee its
credibility and reliability. A review of the literature and discussions with the chil-
dren and their families were conducted in order to identify the concepts related to
the pathology. RESULTS: Exploratory assessments showed that the concept of
burden could be structured around five components: feeling of pain, daily life,
family and personal relationships, work and psychological impact. Ninety-six pre-
liminary items were identified at the end of the first discussion. A first analysis
managed to reduce these items to 40 whilst conserving the 5 components but
making it easier to use the analysis. The creation of a child module aimed at
children who are able to provide answers independently proved necessary.
CONCLUSIONS: Chronic pathologies such as ichthyosis, which remains a rare and
incapacitating illness, are difficult to assess by clinical or quality of life aspects alone as
their impact can be multidimensional. Family Burden Ichthyosis takes them all into
consideration in order to explain every angle of the handicap generated.
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OBJECTIVES: To develop a new instrument measuring neuropathic pain at and
below the level of spinal cord injury (SCI) based on pain intensity, pain interference
and pain descriptors. METHODS: An expert panel composed of pain specialists,
physiologists, rehabilitation doctors, neurologists, psychologists and methodolo-
gists was created to generate the items and to supervise the questionnaire con-
struction, following Classic Test Theory assumptions. A total of 12 Likert items, 2
multichoice items, 7 dichotomous indicators and 23 pain descriptors were pro-
posed. They were measured for at and below level pain in patients with traumatic
SCI between the C3 and T10 level. A subgroup of items was assessed for constant
pain, paroxysmal pain, and evoked pain. Item analysis, structural validity (explor-
atory factor analysis) and reliability (Cronbach’s alpha) were assessed. Correlation
with DN4, NPSI, BPI and MHI5 was studied for convergent validity. Cluster analysis
and multidimensional correspondence analysis were also used to study pain de-
scriptor behavior. RESULTS: A total of 153 patients recruited at 4 specialized hos-
pitals in Spain and Denmark. Women were 26%, and mean age 43 years (SD12.4).
Thirty five percent experienced below SCI level pain, 26% at level, and 39% both.
Factor analysis below SCI suggested that pain intensity and QoL interference were
related to constant non-evoked pain, while paroxysmal pain was related to night
disturbance and temperature-evoked pain. Scale reliability was 0.76 below and 0.80
at SCI level. Exploratory correlations with other standard diagnostic tools were
moderate. Descriptor clustering disclosed 5 main groups of pain types covering
most of the items used frequently in other instruments (DN4 or NPSI). Pain at and
below level differed in specific aspects. CONCLUSIONS: Initial psychometric prop-
erties of the EuroDolMed are good and support the use of this new instrument to
explore neuropathic pain in patients with SCI, although an effort should be made to
shorten it without losing precision.
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OBJECTIVES: To assess public preferences for the predictive genetic test for Alz-
heimer’s disease in the United States. METHODS: A rating conjoint analysis was
conducted using an anonymous online survey distributed by Qualtrics® to a gen-
eral population panel in April 2011 in the United States. The study design included
three attributes: Accuracy, Treatment Availability, and Anonymity. A total of 12
scenarios were used to elicit people’s preference by adopting an 11-point scale. The
respondents also stated their highest willingness-to-pay (WTP) for each scenario
by answering the open-ended questions. RESULTS: A total of 295 responses were
collected over four days. The results showed the most important attribute for the
aggregate model was Accuracy, contributing 64.73% to the preference rating. Treat-
ment Availability and Anonymity contributed 20.72% and 14.59% to the preference
rating, respectively. The most preferred scenario was the test with a 100% chance
of being correct, a cure for AD is available and the test result is anonymous. The
median WTP for the highest-rating scenario (Accuracy 100%, a cure is available,
test result is anonymous) was $100 (mean WTP was $276). The median WTP for the
lowest-rating scenario (Accuracy 40%, no cure but drugs for symptom relief, not
anonymous) was zero (mean WTP was $36). Four groups were identified using
cluster analysis revealing different patterns of importance among the three
attributes. CONCLUSIONS: The results of this study highlight the attributes con-
sumer find important when making the decision to obtain an AD genetic test.
These results should be of interests to policy makers, genetic test developers and
health care providers.
PND51
THE RELATIONSHIP BETWEEN PATIENT-REPORTED HEALTH-RELATED
QUALITY OF LIFE AND DISABILITY STATUS AMONG PATIENTS WITH
MULTIPLE SCLEROSIS
Khalaf KM1, Globe D1, Armstrong E2, Malone D2, Coyne K3
1Allergan, LLC, Irvine, CA, USA, 2University of Arizona, Tucson, AZ, USA, 3United BioSource
Corporation, Bethesda, MD, USA
OBJECTIVES: Previous research suggests that the Short Form 36 (SF-36) may cap-
ture some of the broad effects of MS that are not reflected in the Kurtzke Expanded
Disability Status Scale (EDSS) and may be appropriate when evaluating overall
health-related quality of life (HRQL). The purpose of this study was to explore the
relationship between an EDSS-correlated self-reported disability measure, the Pa-
tient Determined Disease Steps (PDDS), and SF-36 health domain scores.
METHODS: A convenience sample of US-residing participants with MS were re-
cruited through web-based patient advocacy organizations. Participants re-
sponded to questions pertaining to demographics, disease history, productivity,
urinary symptoms, and HRQL. Disability status was measured using the PDDS, an
8-point ordinal scale ranging from “Normal” to “Bedridden,” and general HRQL was
measured using the SF-36 version 2, a 36-item questionnaire comprised of 8 health
domain subscales and 2 summary scores normalized for direct comparison to the
US general population. Spearman rank correlation coefficients were calculated to
assess the relationship between SF-36 health domain scores and PDDS scores.
RESULTS: Among the sample of 1052 participants who completed the survey, 19%
were men and the mean age was 48 years. All 8 SF-36 subscales were significantly
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positively correlated with one another (0.20r0.73), and significantly negatively
correlated with PDDS scores (-0.82r-0.07). The physical functioning domain cor-
related most strongly with PDDS scores (r-0.82, p0.001). Strong correlations
were also noted among the role-physical (r-0.58, p0.001), social functioning
(r-0.37, p0.001), and bodily pain (r-0.28, p0.001) domains. The domains cor-
relating most weakly with PDDS scores were vitality (r-0.23, p0001) and mental
health (r-0.07, p0.03). CONCLUSIONS: As expected, the patient-rated PDDS
scores were more strongly associated with domains related to physical health
status. To capture the broader psychosocial impact of MS on patient HRQL, addi-
tional patient-reported outcomes need to be utilized.
PND52
RESPONSIVENESS OF THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF
LIFE AND SHORT FORM-36 QUESTIONNAIRES TO EXPANDED DISABILITY
STATUS SCALE SCORE CHANGES IN SUBJECTS WITH MULTIPLE SCLEROSIS:
FINAL 24-MONTH RESULTS FROM AN INTERNATIONAL OBSERVATIONAL
STUDY
Fernandez O1, Baumstarck-Barrau K2, Butzkueven H3, Flachenecker P4, Idiman E5,
Pelletier J2, Stecchi S6, Verdun di Cantogno E7, Milner A7, Auquier P2
1Hospital Regional Universitario Carlos Haya, Málaga, Spain, 2Timone University Hospital,
Marseille, France, 3Royal Melbourne Hospital, Melbourne, Australia, 4Neurological Rehabilitation
Center Quellenhof, Bad Wildbad, Germany, 5Dokuz Eylül University, Ýzmir, Turkey, 6Multiple
Sclerosis Unit, Department of Neuroscience AUSL, Bologna, Italy, 7Merck Serono S.A., Geneva,
Switzerland
OBJECTIVES: Quality of life (QoL) is an important measure in multiple sclerosis
(MS), complementing clinical assessments such as the Expanded Disability Status
Scale (EDSS). The MS International QoL (MusiQoL) questionnaire is a validated,
MS-specific instrument. This multicentre, observational study assessed respon-
siveness of MusiQoL versus the Short Form-36 version 2 (SF36v2) to changes in
EDSS score over 24 months in subjects with MS (18 years; EDSS 7.0;
treated/untreated). METHODS: MusiQoL, SF36v2 and EDSS scores were recorded at
baseline (BL) and 6-monthly intervals to month 24 (M24). Primary endpoint: change
in MusiQoL index score and effect size (ES) to M24. Secondary endpoints included
change in MusiQoL and SF36v2 scores and ES (BL–6-monthly assessments).
RESULTS: Six hundred subjects enrolled in 12 countries; 452 had evaluable BL and
M24 EDSS and MusiQoL index data. BL mean (SD) EDSS score was 2.9 (1.9), mean
(SD) MusiQoL index score was 68.5 (14.3), and mean (SD) MusiQoL subscale scores
ranged from 59.8 (25.0) to 85.5 (18.2). EDSS score worsened by M24 in 89 subjects
(19.7% vs expected 30%); mean (SD) change in MusiQoL index score was 0.30 (12.3)
in non-worsened (ES: 0.02) and –2.3 (11.6) in worsened (ES: –0.17) subjects. At M24,
larger (mean [SD]; ES) changes were seen in MusiQoL Relationship with Healthcare
System (–6.0 [16.9]; –0.40) and Sentimental and Sexual Life (–6.4 [26.2]; –0.22) sub-
scale scores for worsened subjects; in Psychological Well-Being (4.8 [21.6]; 0.20)
subscale score for non-worsened subjects; and in the SF36v2 physical component
(–2.5 [6.7]; –0.24), physical functioning (–3.3 [7.6]; –0.28), bodily pain (–3.1 [10.3];
–0.28) and emotional (–2.8 [14.1]; –0.22) subscale scores for worsened subjects.
CONCLUSIONS: MusiQoL index score detected poorer QoL in subjects with wors-
ening EDSS scores. Most MusiQoL scores decreased over 24 months in subjects with
more severe disability, indicating poorer QoL and confirming the utility of the
MS-specific MusiQoL questionnaire in rating QoL.
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OBJECTIVES: Walking impairment is recognised as one of the most distressing
disabilities for people with Multiple Sclerosis (MS) and is reported in approximately
75% of patients. The objective of this analysis is to assess the impact of impaired
walking on quality of life, and on direct and indirect costs to society. METHODS:
The NARCOMS registry is a voluntary MS patient self-report database operating
mainly in the US. The registry collects MS related data semi-annually through
web-based and mail questionnaires, and periodically administers additional sur-
veys on specific topics of interest, such as mobility. One of the main measures used
for assessing walking impairment is the Multiple Sclerosis Walking Scale 12
(MSWS12). The Patient Determined Disease Step (PDDS) scale is used to measure
the level of disease progression. NARCOMS data collection also addresses patient
reported quality of life through the EuroQol-5 Dimensions (EQ-5D) and the 12-item
Short-Form survey (SF-12), as well as patients’ physical activities, work life, and
healthcare resource use. We used descriptive statistics, and univariate analyses to
describe and quantify the cross-sectional relationship between walking impair-
ment and other patient outcomes. RESULTS: A total of 2276 patients were ran-
domly selected from the NARCOMS database, of which 1838 (81%) were female. The
sample population had a mean age of 46 years, and a mean PDDS score of 3.0.
Univariate analysis demonstrated that increases in MSWS-12 scores (decrease in
ambulation) were negatively correlated with quality of life as measured by EQ-5D.
An increase in MSWS-12 score was also associated with increases in visits to MS
neurologists and physiotherapists, increases in caregiver visits, as well as reduced
productivity. CONCLUSIONS: MS patients with less severe walking impairment
showed better quality of life, lower health care utilization and higher productivity.
Additional research using multivariate models should be encouraged to further
characterize the impact of impaired walking on MS patients.
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OBJECTIVES: To evaluate the evidence for quality of life (QoL) impairment, disabil-
ity, healthcare resource use, and economic burden associated with chronic daily
headache (CDH), particularly chronic migraine (CM).METHODS: Systematic review
and qualitative synthesis of studies of patients/subjects with CDH ( 15 headache
days/month) that included CM, reporting QoL or disability outcomes, healthcare
resource utilisation or associated direct costs. RESULTS: Thirty-four studies were
included: 25 of patients; 9 of subjects from the general population; 16 reporting QoL
and 14 reporting disability outcomes; 4 reporting on healthcare resource utilisation
and/or costs. Data were not amenable to statistical pooling. In studies reporting
QoL using SF-36 or SF-12 instruments: CDH was consistently associated with lower
QoL compared to normative/healthy control (5/5 studies) or episodic headache (EH)
(6/6 studies); 3/4 studies showed CDH with migraine was associated with lower QoL
than CDH without migraine; 3/5 studies showed CDH with medication overuse
headache (MOH) was associated with lower QoL than CDH without MOH; 4/4 stud-
ies suggested a significant negative QoL impact when CDH was with a comorbidity.
In studies reporting disability using the MIDAS instrument, CDH was consistently
associated with greater disability and productivity (D&P) loss than EH (7/7 studies),
1/2 studies showed CDH with migrainous features was associated with greater D&P
loss than CDH without migraine, 1/1 studies showed CDH with MOH was associ-
ated with greater D&P loss than CDH without MOH and 1/1 studies suggested a
significant negative impact when CDH was with a named comorbidity. In the two
most comprehensively reported economic studies, CDH was associated with more
consultations, more or longer hospitalisations and higher direct costs compared to
EH.CONCLUSIONS:The findings underline the disabling nature and QoL detriment
of CDH, and in particular of CM and CDH with MOH, and negative impact on work-
place productivity compared to other headache types.
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OBJECTIVES: A number of studies evaluated different predictors of health-related
quality of life (HRQOL) in children and adolescents with epilepsy, but the findings of
these studies were often contradictory and it was not possible to draw general
conclusions. Therefore, this review was organized with the aims to identify in a
systematic way the predictors of HRQOL in pediatric epilepsy.METHODS: Searches
of the literature in Pubmed, Scopus, and Web of Science, with searches of relevant
journals were performed. In total, 14 studies met the inclusion criteria (participant
aged up to 18 years, HRQOL was assessed with an epilepsy specific and/or generic
questionnaire/s, HRQOL predictors were identified using regression models, and
the study was published in a peer-review journal). The methodological quality of
the studies was assessed using predefined criteria. RESULTS: All identified studies
were cross-sectional with the quality scores ranging 7 (low) – 14 (high) points.
Strong evidence was found for age at epilepsy onset (younger age), a number of
antiepileptic drugs (AEDs), and parental depression as HRQOL predictors in both,
children and adolescents. Moderate evidence was found for attention problems,
overall intelligence (lower) and family (i. e. structure, parental anxiety, etc.). Spe-
cific to adolescents with epilepsy, seizure worry/concerns and side effects of AEDs
were found as strong predictors and epilepsy severity, while a number of AEDs as
moderate. Weak evidence and inconclusive data exist for other predictors (i.e.
social skills, duration of epilepsy, seizure frequency and severity, neuropsychiatric
comorbidity, side effects of AEDS, autonomy, social support, victimization, eco-
nomic status, and so forth). CONCLUSIONS: This systematic review identified age
at epilepsy onset, a number of AEDs, and parental depression as strong HRQOL
predictors in pediatric epilepsy, but specific to adolescents only, seizure worry/
concerns and side effects of AEDs were identified. Other predictors were of lesser
importance or were unimportant.
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OBJECTIVES: A growing body of evidence suggests that symptoms of attention-
deficit/hyperactivity disorder (ADHD) persist into adulthood and are associated
with ongoing impairments in quality of life (QoL). The objective of the study was to
identify the most commonly used QoL instruments in adults with ADHD and to
examine their psychometric properties. METHODS: A systematic literature review
was conducted to identify articles from 1990 to May 2011 using PUBMED and Pro-
QoLID. The search was limited to English language and key search terms included
but were not limited to ADHD, quality of life, psychometrics, questionnaires, and
adults. Identified articles were screened further to exclude clinical studies not
measuring QoL, review articles relating to ADHD and QoL, and studies with n 30.
RESULTS: The search yielded a total of 89 articles of which 16 were included in the
final review. The Adult ADHD Quality of Life (AAQoL) and the ADHD Impact Module
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